Lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic deramatitis in two Phase 3 trials
Barcelona (ots/PRNewswire) - - Primary and all key secondary endpoints including itch, interference of itch on sleep and quality of life were met at Week 16 in two pivotal Phase 3 trials - Safety profile consistent with prior lebrikizumab studies in atopic dermatitis Lebrikizumab led to significant improvements with ...